Analyst Reco. Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 18/07/2025 BST			5-day change	1st Jan Change
108.22 ^USD	-0.53%		-1.30%	+17.16%

07-18	Hookipa Pharma announces intention to voluntarily delist and deregister its common stock	RE
07-16	Gilead Sciences Insider Sold Shares Worth $277,575, According to a Recent SEC Filing	MT

Analyst Reco.

HSBC Adjusts Price Target on Gilead Sciences to $91 From $93, Maintains Hold Rating	07-11	MT
RBC Lifts Price Target on Gilead Sciences to $96 From $95, Keeps Sector Perform Rating	07-07	MT
Wolfe Research Adjusts Price Target on Gilead Sciences to $135 From $115	06-20	MT
Analyst recommendations: Lululemon, Micron, Carnival Corp, UnitedHealth…	06-19
RBC Capital Raises Price Target on Gilead Sciences to $95 From $92, Keeps Sector Perform Rating	06-11	MT
DBS Bank Adjusts Price Target on Gilead Sciences to $140 From $125, Maintains Buy Rating	06-02	MT
Mizuho Adjusts Price Target on Gilead Sciences to $117 From $100, Maintains Outperform Rating	05-05	MT
Wolfe Research Adjusts Gilead Sciences Price Target to $115 From $110	05-02	MT
Analyst recommendations: Meta Platforms, Progressive, Equifax, SBA Communications, Cadence Design Systems...	04-29
HSBC Adjusts Gilead Sciences Price Target to $93 From $82, Maintains Hold Rating	04-28	MT
Oppenheimer Adjusts Price Target on Gilead Sciences to $125 From $132, Maintains Outperform Rating	04-25	MT
Goldman Sachs Adjusts Gilead Sciences Price Target to $100 From $97, Maintains Neutral Rating	04-25	MT
Morgan Stanley Raises Price Target on Gilead Sciences to $135 From $130, Keeps Overweight Rating	04-25	MT
RBC Lifts Price Target on Gilead Sciences to $92 From $89, Keeps Sector Perform Rating	04-25	MT
TD Cowen Adjusts Gilead Sciences Price Target to $110 From $100, Maintains Buy Rating	04-23	MT
BMO Capital Adjusts Gilead Sciences Price Target to $120 From $115	04-17	MT
Leerink Partners Adjusts Price Target on Gilead Sciences to $105 From $104, Keeps Outperform Rating	04-17	MT
Goldman Sachs Adjusts Price Target on Gilead Sciences to $97 From $96, Maintains Neutral Rating	04-15	MT
RBC Trims Price Target on Gilead Sciences to $89 From $90, Keeps Sector Perform Rating	04-03	MT
JPMorgan Adjusts Price Target on Gilead Sciences to $130 From $120, Maintains Overweight Rating	03-27	MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $130 From $123, Keeps Overweight Rating	03-11	MT
BofA Securities Adjusts Gilead Sciences Price Target to $126 From $116, Maintains Buy Rating	03-05	MT
Wells Fargo Adjusts Price Target on Gilead Sciences to $140 From $120, Keeps Overweight Rating	03-05	MT
Oppenheimer Adjusts Price Target on Gilead Sciences to $132 From $115, Keeps Outperform Rating	03-04	MT
Jefferies & Co. Adjusts Gilead Sciences Price Target to $130 From $115, Maintains Buy Rating	02-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Time To Grow PFL Fanbase, Revenue: CEO John Martin

July 11, 2025 at 09:09 am